Earnings call transcript: InnoCare Pharma’s Q4 2025 marks first profitable year

InnoCare reported its first full-year profit in 2025 with net profit of RMB 644 million and diluted EPS of RMB 0.38 on revenue up 135% to RMB 2.37–2.38 billion, and RMB 2.8 billion in cash. Management emphasized >$2.5 billion in BD deal value and multiple near-term clinical readouts and NDA plans that underpin growth, while R&D spend (RMB 950 million) and planned investments continue. Market reaction was muted (stock -0.61% post‑earnings) and consensus EPS forecasts remain negative (‑0.02 USD for FY2025/26), so monitor upcoming mid-year data and NDA milestones for material stock movement.

Analysis

Achieving sustained positive cash flow materially shifts optionality: management can fund late-stage global trials and platform investments without near-term capital raises, which reduces bankruptcy/dilution tail risk and makes the company a more attractive M&A or JV counterparty. That optionality compresses the downside from development setbacks (less forced asset sales) but amplifies the upside capture if one or more platform programs validate — the market will reward de-risked, late-stage assets with a step-change re-rating.

The company’s platform mix (small molecules, ADC payload/linker, molecular glues/TCEs) creates asymmetric outcomes across business lines. A differentiated ADC payload that demonstrably widens the therapeutic window will not only reprice the company’s oncology franchise but also create upstream capacity pressure on specialized payload/linker CMOs, which could raise manufacturing lead times and raise competitors’ costs. Conversely, success in broad immune-modulating small molecules (beyond a single dermatology niche) preserves option value that is robust to single-indication entrants, because a small-molecule that meaningfully treats multiple autoimmune indications changes addressable market assumptions.

Partnerships that externalize late-stage commercialization materially de-risk revenue realization but concentrate single-counterparty execution risk: partner funding shortfalls or trial-design missteps can produce outsized equity volatility uncorrelated to underlying clinical data quality. Expect quarter-to-quarter P&L and share-price moves to be lumpy — the right execution strategy is event-driven exposure around discrete milestones with active hedging rather than passive long-only exposure.

Primary risks are binary clinical/regulatory failures and China-specific regulatory/market access moves that can compress price/take rates quickly; these are 1–12 month risks. Primary catalysts are clinical readouts, NDA acceptances, and BD milestones over the next 6–12 months; successful outcomes should re-rate the equity by multiples, while failures can erase a large fraction of market cap within weeks.

Key Decisions for Investors

• Long 688428 (InnoCare) via 9–12 month call spread: buy 12-month at-the-money (ATM) calls and sell 12-month calls ~40% OTM to fund premium. Size: 2–3% of book. Time horizon: 6–12 months to capture multiple clinical/BD catalysts. Risk/reward: max loss = net premium (~100% of position premium); target gross upside 2–3x if one major POC or NDA acceptance occurs. Trim 50% if no positive price action by month 6.
• Event-hedged equity purchase on 688428: buy shares and simultaneously buy a 6-month put ~30% OTM to cap downside. Size: up to 4% of book for core conviction exposure. Rationale: preserves upside to sequencing of platform readouts while limiting tail risk from binary failures or regulatory shocks. Exit: take profits after realized POC or if share rallies >60%; unwind hedge if put time value falls below 20% of initial cost.
• Directional play on partner execution — long ZBIO (Zenas) via 6–9 month OTM calls (25–35% OTM): size 1% of book. Time horizon: 3–9 months. Rationale: market often over-discounts partner pipeline execution risk; successful partner operational updates or financing/earn-outs can drive 50–100%+ option moves. Hard stop: cut premium if implied volatility collapses >40% without corresponding fundamental news.
• Tactical portfolio hedge: if taking material net-long biotech event exposure, short a short-duration China biotech basket (or use single overvalued peer) to isolate company-specific catalysts. Size: hedge ratio 30–50% of biotech gross exposure. Rationale: neutralizes market/systematic biotech drawdowns so returns are driven by company-specific binary events rather than sector rotation.